Skip Nav Destination
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Adult hematopoietic stem cells lacking Hif-1α self-renew normally
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Issue Archive
June 9 2016
In this Issue
Table of Contents
BLOOD FLASHBACK
INSIDE BLOOD COMMENTARIES
PLENARY PAPER
THROMBOSIS AND HEMOSTASIS
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders
Ilenia Simeoni,Jonathan C. Stephens,Fengyuan Hu,Sri V. V. Deevi,Karyn Megy,Tadbir K. Bariana,Claire Lentaigne,Sol Schulman,Suthesh Sivapalaratnam,Minka J. A. Vries,Sarah K. Westbury,Daniel Greene,Sofia Papadia,Marie-Christine Alessi,Antony P. Attwood,Matthias Ballmaier,Gareth Baynam,Emilse Bermejo,Marta Bertoli,Paul F. Bray,Loredana Bury,Marco Cattaneo,Peter Collins,Louise C. Daugherty,Rémi Favier,Deborah L. French,Bruce Furie,Michael Gattens,Manuela Germeshausen,Cedric Ghevaert,Anne C. Goodeve,Jose A. Guerrero,Daniel J. Hampshire,Daniel P. Hart,Johan W. M. Heemskerk,Yvonne M. C. Henskens,Marian Hill,Nancy Hogg,Jennifer D. Jolley,Walter H. Kahr,Anne M. Kelly,Ron Kerr,Myrto Kostadima,Shinji Kunishima,Michele P. Lambert,Ri Liesner,José A. López,Rutendo P. Mapeta,Mary Mathias,Carolyn M. Millar,Amit Nathwani,Marguerite Neerman-Arbez,Alan T. Nurden,Paquita Nurden,Maha Othman,Kathelijne Peerlinck,David J. Perry,Pawan Poudel,Pieter Reitsma,Matthew T. Rondina,Peter A. Smethurst,William Stevenson,Artur Szkotak,Salih Tuna,Christel van Geet,Deborah Whitehorn,David A. Wilcox,Bin Zhang,Shoshana Revel-Vilk,Paolo Gresele,Daniel B. Bellissimo,Christopher J. Penkett,Michael A. Laffan,Andrew D. Mumford,Augusto Rendon,Keith Gomez,Kathleen Freson,Willem H. Ouwehand,Ernest Turro
PERSPECTIVES
BLOOD SPOTLIGHT
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Clinical Trials & Observations
Andrzej Jakubowiak,Massimo Offidani,Brigitte Pégourie,Javier De La Rubia,Laurent Garderet,Kamel Laribi,Alberto Bosi,Roberto Marasca,Jacob Laubach,Ann Mohrbacher,Angelo Michele Carella,Anil K. Singhal,L. Claire Tsao,Mark Lynch,Eric Bleickardt,Ying-Ming Jou,Michael Robbins,Antonio Palumbo
HEMATOPOIESIS AND STEM CELLS
Adult hematopoietic stem cells lacking Hif-1α self-renew normally
Brief Report
Milica Vukovic,Catarina Sepulveda,Chithra Subramani,Amélie V. Guitart,Jasmine Mohr,Lewis Allen,Theano I. Panagopoulou,Jasmin Paris,Hannah Lawson,Arnaud Villacreces,Alejandro Armesilla-Diaz,Deniz Gezer,Tessa L. Holyoake,Peter J. Ratcliffe,Kamil R. Kranc
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Clinical Trials & Observations
Sascha Dietrich,Andreas Pircher,Volker Endris,Frédéric Peyrade,Clemens-Martin Wendtner,George A. Follows,Jennifer Hüllein,Alexander Jethwa,Elena Ellert,Tatjana Walther,Xiyang Liu,Martin J. S. Dyer,Thomas Elter,Tilman Brummer,Robert Zeiser,Michael Hermann,Michael Herold,Wilko Weichert,Claire Dearden,Torsten Haferlach,Martina Seiffert,Michael Hallek,Christof von Kalle,Anthony D. Ho,Anita Gaehler,Mindaugas Andrulis,Michael Steurer,Thorsten Zenz
MYELOID NEOPLASIA
Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts
Sumithira Vasu,Shun He,Carolyn Cheney,Bhavani Gopalakrishnan,Rajeswaran Mani,Gerard Lozanski,Xiaokui Mo,Veronica Groh,Susan P. Whitman,Renate Konopitzky,Christian Kössl,Donna Bucci,David M. Lucas,Jianhua Yu,Michael A. Caligiuri,William Blum,Paul J. Adam,Eric Borges,Bjoern Rueter,Karl-Heinz Heider,Guido Marcucci,Natarajan Muthusamy
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
Iris Z. Uras,Gina J. Walter,Ruth Scheicher,Florian Bellutti,Michaela Prchal-Murphy,Anca S. Tigan,Peter Valent,Florian H. Heidel,Stefan Kubicek,Claudia Scholl,Stefan Fröhling,Veronika Sexl
PLATELETS AND THROMBOPOIESIS
A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss
Simon Stritt,Paquita Nurden,Ernest Turro,Daniel Greene,Sjoert B. Jansen,Sarah K. Westbury,Romina Petersen,William J. Astle,Sandrine Marlin,Tadbir K. Bariana,Myrto Kostadima,Claire Lentaigne,Stephanie Maiwald,Sofia Papadia,Anne M. Kelly,Jonathan C. Stephens,Christopher J. Penkett,Sofie Ashford,Salih Tuna,Steve Austin,Tamam Bakchoul,Peter Collins,Rémi Favier,Michele P. Lambert,Mary Mathias,Carolyn M. Millar,Rutendo Mapeta,David J. Perry,Sol Schulman,Ilenia Simeoni,Chantal Thys,BRIDGE-BPD Consortium,Keith Gomez,Wendy N. Erber,Kathleen Stirrups,Augusto Rendon,John R. Bradley,Chris van Geet,F. Lucy Raymond,Michael A. Laffan,Alan T. Nurden,Bernhard Nieswandt,Sylvia Richardson,Kathleen Freson,Willem H. Ouwehand,Andrew D. Mumford
THROMBOSIS AND HEMOSTASIS
LETTERS TO BLOOD
BLOOD WORK
-
Cover Image
Cover Image
![issue cover]()
Confocal microscopy images of A549 cells transiently transfected with a DIAPH1 R1213* expression construct were stained for F-actin (red), acetylated tubulin (green), and DIAPH1 (cyan). Incubation with the FH2-domain inhibitor SMIFH2 reduced the F-actin content, but not the content of microtubules and acetylated tubulin. See the article by Stritt et al on page 2903.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
